一个随机的,开放的标签,探索性试验,比较阿曼塔丁和罗皮尼罗尔在不安腿综合征中的有效性
Govind Madhaw1, Ravi Gupta2,3, Puneet Dhamija4
1Department of Neurology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
Sleep science (Sao Paulo, Brazil)
|July 10, 2023
概括
阿曼塔丁和罗皮尼罗尔显示了类似的不安腿综合征 (RLS) 症状减少,直到第8周. 罗皮尼罗尔从第10周开始表现出优越性,并且耐受性更好,更有效地改善生活质量和失眠.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 不安腿综合征 (RLS) 是一种神经疾病,其特点是不可抗拒的动腿冲动.
- 阿曼塔丁具有抗谷氨酸和多巴胺作用,是RLS的潜在治疗剂.
- 罗皮尼罗尔是一种多巴胺激动剂,通常用于RLS治疗.
研究的目的:
- 为了比较阿曼塔丁与罗皮尼罗尔在治疗RLS中的疗效和安全性.
- 评估这些治疗对RLS症状严重程度,生活质量和失眠的影响.
主要方法:
- 这是一项为期12周的随机化,开放式,灵活剂量研究.
- 具有国际RLS研究小组严重程度等级得分 (IRLSS) >10的患者随机分配给阿曼塔丁 (100-300mg/天) 或罗皮尼罗尔 (0.5-2mg/天).
- 主要结局是12周的IRLSS与基线的变化;次要结局包括RLS-QOL,ISI,CGI-I和不良事件.
主要成果:
- 阿曼塔丁和罗皮尼罗尔两组都显示了可比的IRLSS,直到第8周.
- 罗皮尼罗尔从第10周到第12周显示出优异的IRLSS降低 (12周IRLSS:9.0 ± 4.4对比17.0 ± 5.7;P<0.001).
- 在第12周,罗皮尼罗尔还在失眠严重程度指数 (ISI) 和与RLS相关的生活质量 (RLS-QOL) 中表现出更好的改善.
结论:
- 阿曼塔丁和罗皮尼罗尔提供相当于RLS症状缓解,直到第8周.
- 从第10周开始,罗皮尼罗尔的疗效优越,并且耐受性更好.
- 这两种治疗都改善了睡眠和生活质量,而罗宾罗尔显示出了优势.
关键词:
阿曼塔丁 (Amantadine) 是一种药物.多巴胺激动剂是多巴胺激动剂.失眠是一种失眠.N-甲基-D-亚斯巴拉基酸是什么焦躁腿综合征是什么意思罗皮尼罗尔 (Ropinirole) 是一种制剂.更多相关视频
03:53Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
Published on: March 15, 2024
1.8K
06:18Assessing the Autonomic and Behavioral Effects of Passive Motion in Rats using Elevator Vertical Motion and Ferris-Wheel Rotation
Published on: February 7, 2020
7.5K
相关概念视频
Restless Leg Syndrome and Night Terrors
210
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
210
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.4K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.4K
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
